Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Women's Health | 14 | 2021 | 246 | 1.770 |
Why?
|
Metabolic Syndrome | 6 | 2020 | 65 | 1.770 |
Why?
|
Adiposity | 8 | 2018 | 47 | 1.560 |
Why?
|
Menopause | 9 | 2021 | 134 | 1.530 |
Why?
|
Intra-Abdominal Fat | 6 | 2021 | 42 | 1.360 |
Why?
|
Obesity | 6 | 2018 | 292 | 1.230 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2015 | 200 | 1.110 |
Why?
|
Cardiovascular Diseases | 8 | 2021 | 402 | 1.030 |
Why?
|
Ecosystem | 1 | 2023 | 27 | 0.950 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 138 | 0.930 |
Why?
|
Thrombosis | 2 | 2014 | 60 | 0.890 |
Why?
|
Middle Aged | 36 | 2021 | 9818 | 0.880 |
Why?
|
Obesity, Abdominal | 4 | 2015 | 22 | 0.860 |
Why?
|
Adrenal Gland Diseases | 2 | 2012 | 3 | 0.790 |
Why?
|
Female | 43 | 2021 | 16205 | 0.760 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 195 | 0.750 |
Why?
|
Abdominal Fat | 3 | 2021 | 10 | 0.700 |
Why?
|
Diet Therapy | 1 | 2018 | 9 | 0.680 |
Why?
|
Weight Reduction Programs | 1 | 2018 | 17 | 0.660 |
Why?
|
Humans | 47 | 2023 | 29351 | 0.650 |
Why?
|
Behavior Therapy | 1 | 2018 | 76 | 0.640 |
Why?
|
Risk Factors | 20 | 2021 | 2436 | 0.630 |
Why?
|
Atherosclerosis | 3 | 2021 | 72 | 0.630 |
Why?
|
Exercise Therapy | 1 | 2018 | 112 | 0.620 |
Why?
|
Hydrocortisone | 3 | 2012 | 43 | 0.610 |
Why?
|
Testosterone | 2 | 2014 | 32 | 0.600 |
Why?
|
Waist-Height Ratio | 1 | 2016 | 6 | 0.590 |
Why?
|
Adult | 22 | 2021 | 8594 | 0.590 |
Why?
|
Metabolic Diseases | 1 | 2016 | 14 | 0.590 |
Why?
|
United States | 15 | 2021 | 2331 | 0.580 |
Why?
|
Mass Screening | 1 | 2016 | 177 | 0.530 |
Why?
|
Cognition Disorders | 2 | 2020 | 1011 | 0.500 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 42 | 0.480 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 11 | 0.460 |
Why?
|
Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.450 |
Why?
|
Prevalence | 4 | 2016 | 486 | 0.440 |
Why?
|
Hemodynamics | 1 | 2012 | 83 | 0.440 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2009 | 8 | 0.430 |
Why?
|
Postmenopause | 6 | 2019 | 61 | 0.430 |
Why?
|
Liver Cirrhosis | 1 | 2012 | 60 | 0.430 |
Why?
|
Lipoproteins, HDL | 3 | 2014 | 28 | 0.420 |
Why?
|
Blood Glucose Self-Monitoring | 2 | 2009 | 4 | 0.420 |
Why?
|
Carotid Intima-Media Thickness | 2 | 2021 | 24 | 0.410 |
Why?
|
Perimenopause | 3 | 2021 | 24 | 0.390 |
Why?
|
Biomarkers | 5 | 2020 | 691 | 0.390 |
Why?
|
Longitudinal Studies | 9 | 2020 | 1442 | 0.380 |
Why?
|
Follow-Up Studies | 9 | 2020 | 1829 | 0.380 |
Why?
|
Diastole | 1 | 2010 | 32 | 0.370 |
Why?
|
Absorptiometry, Photon | 3 | 2015 | 76 | 0.370 |
Why?
|
Adrenal Insufficiency | 1 | 2009 | 7 | 0.370 |
Why?
|
Cardiomyopathies | 1 | 2010 | 29 | 0.360 |
Why?
|
Vitamin D | 1 | 2010 | 31 | 0.360 |
Why?
|
Blood Glucose | 5 | 2020 | 112 | 0.360 |
Why?
|
Pituitary Diseases | 1 | 2008 | 3 | 0.340 |
Why?
|
Hypothalamic Diseases | 1 | 2008 | 6 | 0.340 |
Why?
|
Reproducibility of Results | 4 | 2014 | 788 | 0.340 |
Why?
|
Algorithms | 3 | 2023 | 400 | 0.330 |
Why?
|
Hypertension | 4 | 2021 | 266 | 0.320 |
Why?
|
Body Mass Index | 5 | 2018 | 426 | 0.320 |
Why?
|
Socioeconomic Factors | 4 | 2023 | 327 | 0.310 |
Why?
|
Prospective Studies | 6 | 2020 | 1808 | 0.310 |
Why?
|
Depression | 3 | 2018 | 465 | 0.300 |
Why?
|
Population Surveillance | 2 | 2020 | 116 | 0.300 |
Why?
|
Cohort Studies | 7 | 2020 | 1937 | 0.290 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 552 | 0.290 |
Why?
|
Exercise | 3 | 2018 | 467 | 0.290 |
Why?
|
Prognosis | 3 | 2020 | 840 | 0.280 |
Why?
|
Risk Assessment | 3 | 2020 | 679 | 0.280 |
Why?
|
Male | 13 | 2020 | 15633 | 0.280 |
Why?
|
Ketone Bodies | 1 | 2005 | 5 | 0.270 |
Why?
|
Incidence | 5 | 2020 | 752 | 0.260 |
Why?
|
ROC Curve | 3 | 2009 | 138 | 0.260 |
Why?
|
Economic Development | 1 | 2023 | 4 | 0.240 |
Why?
|
Diet | 2 | 2019 | 171 | 0.240 |
Why?
|
Estradiol | 4 | 2021 | 58 | 0.240 |
Why?
|
Developing Countries | 1 | 2023 | 21 | 0.240 |
Why?
|
Insulin | 2 | 2011 | 92 | 0.240 |
Why?
|
Pregnanediol | 2 | 2021 | 6 | 0.240 |
Why?
|
Luteinizing Hormone | 2 | 2021 | 12 | 0.240 |
Why?
|
Chicago | 5 | 2014 | 865 | 0.240 |
Why?
|
Pharmacoepidemiology | 2 | 2020 | 5 | 0.240 |
Why?
|
Energy Intake | 3 | 2019 | 66 | 0.230 |
Why?
|
Life Style | 2 | 2018 | 211 | 0.230 |
Why?
|
Atrial Appendage | 2 | 2014 | 45 | 0.230 |
Why?
|
Hypoglycemic Agents | 1 | 2003 | 56 | 0.220 |
Why?
|
Waist Circumference | 4 | 2016 | 36 | 0.220 |
Why?
|
Energy Metabolism | 2 | 2018 | 52 | 0.220 |
Why?
|
Aged | 11 | 2020 | 9441 | 0.220 |
Why?
|
Stroke Volume | 2 | 2014 | 56 | 0.210 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 306 | 0.210 |
Why?
|
Menstrual Cycle | 2 | 2021 | 27 | 0.210 |
Why?
|
Hyperglycemia | 2 | 2020 | 34 | 0.210 |
Why?
|
Progesterone | 1 | 2021 | 26 | 0.200 |
Why?
|
Cosyntropin | 2 | 2012 | 3 | 0.200 |
Why?
|
Carotid Artery Diseases | 1 | 2021 | 44 | 0.190 |
Why?
|
Multimorbidity | 1 | 2020 | 8 | 0.190 |
Why?
|
Insulin Resistance | 4 | 2011 | 59 | 0.190 |
Why?
|
Cholesterol, HDL | 3 | 2011 | 27 | 0.190 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 96 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 63 | 0.180 |
Why?
|
Seasons | 1 | 2019 | 31 | 0.180 |
Why?
|
Cerebral Hemorrhage | 1 | 2020 | 129 | 0.170 |
Why?
|
Antidepressive Agents | 1 | 2019 | 100 | 0.170 |
Why?
|
Appetite | 1 | 2018 | 5 | 0.170 |
Why?
|
Antihypertensive Agents | 1 | 2019 | 85 | 0.170 |
Why?
|
Fractures, Bone | 1 | 2019 | 73 | 0.160 |
Why?
|
Body Weight | 1 | 2018 | 133 | 0.160 |
Why?
|
Weight Gain | 1 | 2018 | 66 | 0.160 |
Why?
|
Chronic Disease | 1 | 2020 | 495 | 0.160 |
Why?
|
Weight Loss | 1 | 2018 | 99 | 0.160 |
Why?
|
Hormones | 1 | 2017 | 13 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 441 | 0.150 |
Why?
|
Depressive Disorder | 1 | 2018 | 187 | 0.150 |
Why?
|
Time Factors | 4 | 2020 | 1615 | 0.150 |
Why?
|
Social Support | 1 | 2018 | 185 | 0.150 |
Why?
|
Sleep Wake Disorders | 1 | 2018 | 148 | 0.150 |
Why?
|
Beverages | 1 | 2016 | 10 | 0.150 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 521 | 0.140 |
Why?
|
Retrospective Studies | 5 | 2014 | 3273 | 0.140 |
Why?
|
Cross-Sectional Studies | 3 | 2009 | 958 | 0.140 |
Why?
|
Child | 3 | 2009 | 1345 | 0.140 |
Why?
|
Climacteric | 1 | 2015 | 10 | 0.140 |
Why?
|
False Positive Reactions | 1 | 2015 | 33 | 0.130 |
Why?
|
Estrogens | 1 | 2015 | 33 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 18 | 0.130 |
Why?
|
Immunoassay | 1 | 2015 | 41 | 0.130 |
Why?
|
Carbonated Beverages | 1 | 2014 | 2 | 0.130 |
Why?
|
Research Report | 1 | 2014 | 7 | 0.130 |
Why?
|
Waist-Hip Ratio | 1 | 2014 | 16 | 0.130 |
Why?
|
Sweetening Agents | 1 | 2014 | 7 | 0.130 |
Why?
|
Birth Weight | 1 | 2015 | 34 | 0.130 |
Why?
|
Meals | 1 | 2014 | 12 | 0.130 |
Why?
|
Age Factors | 3 | 2020 | 839 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 770 | 0.130 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 24 | 0.130 |
Why?
|
Illinois | 2 | 2013 | 241 | 0.130 |
Why?
|
Hyperandrogenism | 1 | 2014 | 1 | 0.120 |
Why?
|
Oligomenorrhea | 1 | 2014 | 2 | 0.120 |
Why?
|
Self Report | 3 | 2020 | 218 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2014 | 47 | 0.120 |
Why?
|
Echocardiography, Transesophageal | 1 | 2014 | 44 | 0.120 |
Why?
|
Body Image | 1 | 2014 | 31 | 0.120 |
Why?
|
Employment | 1 | 2013 | 42 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 22 | 0.110 |
Why?
|
Body Fat Distribution | 1 | 2012 | 12 | 0.110 |
Why?
|
Blood Pressure | 4 | 2019 | 238 | 0.110 |
Why?
|
Logistic Models | 3 | 2019 | 405 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 162 | 0.110 |
Why?
|
Motor Activity | 2 | 2018 | 369 | 0.110 |
Why?
|
Cognitive Dysfunction | 1 | 2021 | 938 | 0.100 |
Why?
|
Up-Regulation | 1 | 2012 | 177 | 0.100 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 340 | 0.100 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.100 |
Why?
|
Neuropsychological Tests | 2 | 2021 | 1251 | 0.100 |
Why?
|
Ultrasonography | 1 | 2013 | 226 | 0.100 |
Why?
|
Breast Neoplasms | 2 | 2015 | 328 | 0.100 |
Why?
|
Calcifediol | 1 | 2010 | 2 | 0.090 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2010 | 3 | 0.090 |
Why?
|
Infant | 2 | 2009 | 531 | 0.090 |
Why?
|
Pericardium | 1 | 2010 | 20 | 0.090 |
Why?
|
Metyrapone | 1 | 2009 | 1 | 0.090 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 42 | 0.090 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 10 | 0.090 |
Why?
|
Particle Size | 1 | 2010 | 78 | 0.090 |
Why?
|
Child, Preschool | 2 | 2009 | 642 | 0.090 |
Why?
|
Reference Standards | 1 | 2009 | 33 | 0.090 |
Why?
|
Antimetabolites | 1 | 2009 | 14 | 0.090 |
Why?
|
Aged, 80 and over | 3 | 2018 | 4844 | 0.090 |
Why?
|
Alcohol Drinking | 1 | 2010 | 76 | 0.090 |
Why?
|
Follicle Stimulating Hormone | 2 | 2021 | 24 | 0.090 |
Why?
|
Hospitals, Public | 1 | 2009 | 30 | 0.090 |
Why?
|
Regression Analysis | 1 | 2010 | 297 | 0.090 |
Why?
|
Health Behavior | 1 | 2010 | 159 | 0.090 |
Why?
|
Fasting | 1 | 2008 | 13 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2008 | 14 | 0.080 |
Why?
|
Urban Population | 1 | 2009 | 143 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2012 | 1111 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2008 | 67 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2007 | 12 | 0.080 |
Why?
|
Burns | 1 | 2007 | 21 | 0.080 |
Why?
|
Carotid Arteries | 2 | 2021 | 54 | 0.070 |
Why?
|
Linear Models | 2 | 2018 | 254 | 0.070 |
Why?
|
Adolescent | 2 | 2009 | 2275 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2007 | 162 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 193 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2007 | 301 | 0.060 |
Why?
|
Lamin Type A | 1 | 2004 | 1 | 0.060 |
Why?
|
Lipodystrophy | 1 | 2004 | 1 | 0.060 |
Why?
|
Acyltransferases | 1 | 2004 | 3 | 0.060 |
Why?
|
GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2004 | 79 | 0.060 |
Why?
|
Gluconeogenesis | 1 | 2003 | 4 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 284 | 0.060 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2003 | 11 | 0.060 |
Why?
|
Young Adult | 1 | 2009 | 1933 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2003 | 19 | 0.060 |
Why?
|
Fatty Acids | 1 | 2003 | 38 | 0.060 |
Why?
|
Triglycerides | 2 | 2014 | 41 | 0.060 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2014 | 343 | 0.060 |
Why?
|
Pulse Wave Analysis | 1 | 2021 | 4 | 0.050 |
Why?
|
Ankle Brachial Index | 1 | 2021 | 6 | 0.050 |
Why?
|
Liver | 1 | 2003 | 173 | 0.050 |
Why?
|
Patient Selection | 1 | 2003 | 232 | 0.050 |
Why?
|
Surveys and Questionnaires | 3 | 2015 | 1181 | 0.050 |
Why?
|
Vasomotor System | 1 | 2021 | 5 | 0.050 |
Why?
|
Cognition | 1 | 2009 | 1279 | 0.050 |
Why?
|
Affect | 1 | 2021 | 64 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2003 | 333 | 0.050 |
Why?
|
Morbidity | 1 | 2020 | 63 | 0.050 |
Why?
|
Hypertriglyceridemia | 2 | 2014 | 20 | 0.050 |
Why?
|
Disease Progression | 1 | 2003 | 788 | 0.050 |
Why?
|
Diet Surveys | 1 | 2019 | 18 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 34 | 0.040 |
Why?
|
Healthy Aging | 1 | 2018 | 14 | 0.040 |
Why?
|
Genetic Testing | 1 | 2018 | 64 | 0.040 |
Why?
|
Osteoporosis | 1 | 2019 | 80 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 321 | 0.040 |
Why?
|
Accidental Falls | 1 | 2019 | 116 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 317 | 0.040 |
Why?
|
Corpus Luteum | 1 | 2017 | 3 | 0.040 |
Why?
|
Estrone | 1 | 2017 | 6 | 0.040 |
Why?
|
Premenopause | 1 | 2017 | 20 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 301 | 0.040 |
Why?
|
Genotype | 1 | 2018 | 405 | 0.040 |
Why?
|
Sleep | 1 | 2020 | 313 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 24 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2015 | 26 | 0.030 |
Why?
|
E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 58 | 0.030 |
Why?
|
Androgens | 1 | 2014 | 8 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2015 | 324 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2015 | 636 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2014 | 173 | 0.030 |
Why?
|
Tunica Intima | 1 | 2011 | 26 | 0.020 |
Why?
|
Nutrition Policy | 1 | 2010 | 6 | 0.020 |
Why?
|
Dietary Fats | 1 | 2010 | 22 | 0.020 |
Why?
|
Vegetables | 1 | 2010 | 15 | 0.020 |
Why?
|
France | 1 | 2010 | 35 | 0.020 |
Why?
|
Fruit | 1 | 2010 | 24 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 75 | 0.020 |
Why?
|
Cross-Cultural Comparison | 1 | 2010 | 41 | 0.020 |
Why?
|
Stroke | 1 | 2014 | 293 | 0.020 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2009 | 15 | 0.020 |
Why?
|
Biological Availability | 1 | 2009 | 26 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 324 | 0.020 |
Why?
|
Aging | 1 | 2018 | 1599 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 33 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 30 | 0.020 |
Why?
|
Knowledge | 1 | 2007 | 19 | 0.020 |
Why?
|
Lipids | 1 | 2007 | 36 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2015 | 3475 | 0.020 |
Why?
|
Length of Stay | 1 | 2007 | 317 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2004 | 9 | 0.020 |
Why?
|
1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.020 |
Why?
|
Consanguinity | 1 | 2004 | 4 | 0.020 |
Why?
|
Hyperinsulinism | 1 | 2004 | 4 | 0.020 |
Why?
|
Pennsylvania | 1 | 2004 | 14 | 0.020 |
Why?
|
RNA Splice Sites | 1 | 2004 | 3 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2004 | 5 | 0.020 |
Why?
|
Exons | 1 | 2004 | 34 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2004 | 47 | 0.020 |
Why?
|
Homozygote | 1 | 2004 | 23 | 0.020 |
Why?
|
Haplotypes | 1 | 2004 | 61 | 0.020 |
Why?
|
Alleles | 1 | 2004 | 224 | 0.010 |
Why?
|
Calcium | 1 | 2007 | 499 | 0.010 |
Why?
|
Phenotype | 1 | 2004 | 355 | 0.010 |
Why?
|